Results 71 to 80 of about 5,545 (148)

IL‐33 Drives Inflammatory Changes and Extracellular Trap Formation in Eosinophils Involving Oxidised LDL and Complement Pathways

Allergy, EarlyView.
IL‐33 induces inflammatory gene signatures in eosinophils, characterised by the upregulation of cell surface markers, inflammatory mediators and regulatory factors, all of which were also observed in nasal polyp‐derived eosinophils. Ox‐LDL and complement fragments (C3a and C5a) promote eosinophil adhesion and survival.
Emiko Matsuyama, Jun Miyata, Takao Mochimaru, Ryuta Onozato, Yo Otsu, Hisashi Sasaki, Keeya Sunata, Shinichi Okuzumi, Katsunori Masaki, Hiroki Kabata, Keinosuke Hizuka, Yoshinori Hasegawa, Ryo Konno, Yusuke Kawashima, Makoto Arita, Shigeharu Ueki, Koichi Fukunaga   +16 more
wiley   +1 more source

Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab [PDF]

, 2008
BACKGROUND The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause.
Frewer, Paul I. H., Gleich, Gerald J., Griffin, Elaine F., Haig, Ann E., Kahn, Jean E., Klion, Amy D., Parkin, Jacqueline M., Ring, Johannes, Rosenwasser, Lanny J., Rothenberg, Marc E., Roufosse, Florence E., Schwartz, Lawrence B., Simon, Hans-Uwe, Weller, Peter F.   +13 more
core   +1 more source

Is Asthma Remission a New Achievable Goal? A Review of the Current Drug‐Related Evidence and Predictors

Allergy, EarlyView.
ABSTRACT Advances in asthma therapies have shown that clinical remission may be an achievable therapeutic goal for patients with asthma. This review discusses the current definitions of remission in asthma, the predictors of remission, airway inflammation/epithelial damage in asthma remission, airway remodeling, paradigms in defining remission and ...
Fatma Esra Gunaydin, Giulia Marcassa, Bianca Olivieri, Gianenrico Senna, Marco Caminati   +4 more
wiley   +1 more source

How safe are the biologicals in treating asthma and rhinitis? [PDF]

, 2009
A number of biological agents are available or being investigated for the treatment of asthma and rhinitis. The safety profiles of these biologic agents, which may modify allergic and immunological diseases, are still being elucidated.
Linda S Cox, ED Bateman, R Naclerio, TW Guilbert, T Bongartz, L Carmona, FE Simons, AFC Gonzalez-Perez, HA Sampson, WJ Pichler, DW MacGlashan Jr, H Lin, C Prussin, H Lin, T Nagakura, TB Casale, H Milgrom, W Busse, Expert Panel Report 3 (EPR-3), M Humbert, D Aaronson, SL Limb, L Cox, FDA, AA Cruz, L Jacobsen, SR Durham, A Des Roches, SJ Till, SR Durham, GE Stewart 2nd, DG Tinkelman, L Cox, AI Tabar, MJ Reid, RF Lockey, DI Bernstein, HS Amin, B Bohle, LS Cox, EH Dunsky, AO Eifan, A Antico, L Blazowski, MM Cochard, H Groot, TB Casale, PS Creticos, DI Bernstein, KJ Drachenberg, KJ Drachenburg, N Mothes, KJ Drachenberg, KJ Drachenberg, TK Hart, P Flood-Page, JK Garrett, ML Stein, S Wenzel, MA Berry, SE Wenzel, JC Davis Jr, V Gerloni, JP Leombruno, FDA, C Botsios, D Furst, E Toussirot, GA Settipane   +68 more
core   +1 more source

Cost-effectiveness analysis of the use of mepolizumab in omalizumab-resistant patients with severe asthma

Качественная клиническая практика, 2019
Objective. To determine the clinical and economic consequences of the drug mepolizumab in patients with severe bronchial asthma (SBA) and the ineff ectiveness of omalizumab. Methods.
A. G. Tolkushin, V. A. Rogov, D. A. Ivanov, N. L. Pogudina   +3 more
doaj   +1 more source

Genetic basis for personalized medicine in asthma [PDF]

, 2012
There is heterogeneity in patient responses to current asthma medications. Significant progress has been made identifying genetic polymorphisms that influence the efficacy and potential for adverse effects to asthma drugs, including; β2-adrenergic ...
Asano, Barnes, Basu, Bleecker, Bleecker, Choudhry, Corren, Currie, Drazen, Drysdale, Duan, Duroudier, Ferreira, Finotto, Gaston, Gudbjartsson, Haldar, Hall, Hammad, Hawkins, Hawkins, Hayakawa, Himes, Holloway, Ian Sayers, Israel, Jin, Kang, Kearley, Kim, Klotsman, Koster, Lee, Lee, Lima, Lima, Litonjua, Liu, Maarsingh, Malmstrom, Mastalerz, Meurs, Michael Portelli, Moffatt, Moffatt, Moore, Mougey, Obeidat, Ober, Oshikawa, Panebra, Panebra, Pascual, Prefontaine, Reihsaus, Risma, Sampson, Savenije, Sayers, Sayers, Slager, Sleiman, Stevens, Tantisira, Tantisira, Tantisira, Tantisira, Torgerson, Trian, Tse, Vonk, Wechsler, Wenzel, Whalen, Whelan, Ye, York   +76 more
core   +2 more sources

Molecularly targeted therapies for asthma: current development, challenges and potential clinical translation [PDF]

, 2016
Extensive research into the therapeutics of asthma has yielded numerous effective interventions over the past few decades. However, adverse effects and ineffectiveness of most of these medications especially in the management of steroid resistant severe ...
Lim, Jonathan Chee Woei, Soo, Hon Liong, Stanslas, Johnson, Sulaiman, Ibrahim   +3 more
core   +1 more source

Coexisting Asthma and Diabetes Are Associated With Adverse Metabolic and Inflammatory Profiles

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Asthma and diabetes frequently co‐occur and share metabolic and inflammatory features, yet the cardiometabolic profile associated with their coexistence is not well defined. We examined differences in cardiometabolic and inflammatory biomarkers by joint asthma–diabetes status in U.S.
Sixtus Aguree, Patricia Silveyra, Nianjun Liu, Arthur H. Owora, Tesfaye B. Mersha   +4 more
wiley   +1 more source

Effectiveness of low-dose mepolizumab in refractory eosinophilic granulomatosis with polyangiitis: systemic steroid use and remission [PDF]

The Korean Journal of Internal Medicine
Background/Aims This study investigated the clinical efficacy of low-dose mepolizumab (100 mg) in controlling severe eosinophilic asthma, aiming to induce eosinophilic granulomatosis with polyangiitis (EGPA) remission and reduce systemic steroid usage ...
Mi-Ae Kim, Ji-Hyun Lee, Eun-Kyung Kim, Jung-Hyun Kim, Jisoo Park, Se Hee Lee, Tae-Bum Kim   +6 more
doaj   +1 more source

Chinese Position Paper on Biologic Therapy for Allergic Rhinitis

Allergy, Volume 81, Issue 5, Page 1354-1369, May 2026.
ABSTRACT Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to ...
Yuan Zhang, Jingyun Li, Xian Li, Menglin Wang, Xiangli Yang, Li Shi, Zhiwei Cao, Yan Feng, Weiwei Liu, Zhendong Xu, Ruixia Ma, Xiaoping Gao, Wen Liu, Jinmei Xue, Xiaoyong Ren, Xuezhong Li, Xicheng Song, Yi Yang, Fang Quan, Lei Cheng, Weihong Jiang, Huabin Li, Jian Li, Huanhai Liu, Jianfeng Liu, Zheng Liu, Wei Lv, Qianhui Qiu, Xiangdong Wang, Yu Xu, Yuanteng Xu, Qintai Yang, Yucheng Yang, Jing Ye, Hongmeng Yu, Dongdong Zhu, Chengshuo Wang, Luo Zhang   +37 more
wiley   +1 more source